^
Association details:
Biomarker:No biomarker
Cancer:Peritoneal Cancer
Drug:Zejula (niraparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
Title:

Niraparib (Zejula) is accepted for use within NHSScotland

Published date:
04/09/2021
Excerpt:
Niraparib (Zejula) is accepted for use within NHSScotland...as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III or IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
ZEJULA is a poly(ADP-ribose) polymerase (PARP) inhibitor indicated:...for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy.
Evidence Level:
Sensitive: A1 - Approval
New
Excerpt:
Zejula is indicated:...as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy

Published date:
02/17/2021
Excerpt:
Niraparib is recommended for use within the Cancer Drugs Fund as an option for maintenance treatment for advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Secondary therapy:
Chemotherapy
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Acceptable Recurrence Therapies for…Peritoneal Cancer: Targeted Therapy...Niraparib